HODGKIN LYMPHOMA

This phase 2 trial is testing whether adding the immunotherapy drug pembrolizumab to standard GVD chemotherapy can improve outcomes for people with Hodgkin lymphoma that has returned or not responded to initial treatment. About 257 participants will receive up to 4 cycles of the …

This early-stage trial tests a new type of immune cell therapy for people with several kinds of blood cancers that have come back or stopped responding to treatment. The therapy uses natural killer (NK) cells from donated cord blood, which are genetically modified to better recog…

This study tests a new drug called AZD3470, alone or with pembrolizumab (Keytruda), in people with certain blood cancers like lymphoma. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 161 adults and teens will take part.

This study is testing whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) while still being effective. The trial involves 260 adults with b…

This study tests two drugs—nivolumab and ruxolitinib—together in people whose Hodgkin lymphoma has returned or not responded to treatment. The goal is to find the safest dose of ruxolitinib when combined with a fixed dose of nivolumab, and to see if the combination can control th…

This early-phase study tests a new approach for people with certain blood cancers (like lymphoma) that have returned or not responded to standard therapy. Participants receive their own immune cells that have been modified to attack cancer cells, along with specially edited stem …

This study tests a new treatment for people with blood cancers like leukemia, lymphoma, and multiple myeloma that have returned or not responded to treatment. Participants receive chemotherapy followed by specially engineered natural killer (NK) cells from donated cord blood. The…

This study tests whether giving donor white blood cells (lymphocytes) soon after a stem cell transplant can lower the chance of cancer returning in people with high-risk blood cancers like leukemia or lymphoma. Participants receive chemotherapy, a stem cell transplant, and then a…

This study provides unlicensed cord blood units for transplant to children and adults with blood cancers, immune disorders, and other serious diseases. The goal is to see how well patients recover their white blood cells after the transplant. By making more cord blood units avail…

This early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …

This phase 3 trial compares two chemotherapy combinations (ABVD and A2VD) for people with newly diagnosed, early-stage Hodgkin lymphoma. About 1,042 participants will receive 3-4 cycles of chemo, with a PET scan after 2 cycles to tailor further treatment. The goal is to see which…

This study tests a stem cell transplant from half-matched (haploidentical) donors for people with various blood cancers. Before the transplant, patients receive chemotherapy and low-dose radiation to prepare their body. The goal is to replace diseased bone marrow with healthy don…

This study is checking how well the drug brentuximab vedotin works for adults with Hodgkin lymphoma who have had a stem cell transplant. Researchers will track 70 participants for about 2 years to see if the drug helps prevent the cancer from coming back. It is an observational s…

This study tests whether a drug called a PD-1 inhibitor can help keep Hodgkin lymphoma from coming back after a stem cell transplant. It is for people whose lymphoma returned or did not respond to earlier treatments. About 83 adults will receive the drug as maintenance therapy an…

This study tests a combination of four drugs (mosunetuzumab, polatuzumab, tafasitamab, and lenalidomide) in people with relapsed B-cell non-Hodgkin lymphoma. The goal is to see if this mix can shrink tumors or stop the cancer from growing. About 36 adults who have already tried o…

This phase 3 trial compares two drug combinations given after a stem cell transplant to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The study will enroll 572 adults with blood cancers like leukemia or myelodysplasi…

This study tests whether a cord blood transplant can help children and young adults (up to age 26) with blood cancers like leukemia and lymphoma. Participants receive the transplant as their first or second treatment. The main goal is to see how many are cancer-free one year afte…

This phase II trial tests different drug combinations to prevent graft-versus-host disease (GVHD) in 400 blood cancer patients receiving stem cell transplants from unrelated donors. Participants will receive either thymoglobulin or a combination of cyclophosphamide with other imm…

This phase 2 trial is testing whether a combination of drugs called BV-AVD works well for people with newly diagnosed, early-stage bulky Hodgkin lymphoma. The study uses PET scans to guide treatment and includes about 71 participants. The goal is to see if this approach can stop …

This early-phase trial tests whether two drugs, ruxolitinib and abatacept, can prevent graft-versus-host disease (GVHD) and cytokine release syndrome in people receiving stem cell transplants from half-matched donors. About 41 adults with blood cancers will take these drugs aroun…

This study tests whether a prebiotic supplement called resistant starch can improve gut microbiome diversity in people with multiple myeloma or lymphoma after an autologous stem cell transplant. Thirty participants will take either the prebiotic or a placebo for about 10 days bef…

This early-stage study is testing an experimental drug called CTX-8371 in people with advanced lung, breast, lymphoma, head and neck, or skin cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 parti…

This early-phase study tests an experimental oral drug called AUR108 in adults with relapsed advanced lymphomas. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. About 40 participants will take the pill, and researchers will m…

This study is testing whether a drug called polatuzumab vedotin can safely help control lymphoma after a stem cell transplant. About 20 people with B-cell or Hodgkin lymphoma who have had a relapse or not responded to prior treatment will receive the drug if their disease is stab…

This study tracks side effects of the drug ADCETRIS (brentuximab vedotin) when given with standard chemotherapy to children and teenagers with untreated CD30-positive Hodgkin lymphoma. The main focus is on serious side effects like low blood counts, nerve damage, and lung problem…

This early-phase trial tests a new approach for people with certain lymphomas that have come back or not responded to treatment. Researchers take immune cells from healthy donors, modify them to recognize and attack CD30-positive cancer cells, and add a molecule (C7R) to boost th…

This study compares two first-line treatments for advanced Hodgkin lymphoma. One group gets a new combination of the immunotherapy drug nivolumab plus chemotherapy (AVD), while the other group receives standard chemotherapy (BEACOPP-like). The goal is to see which approach is saf…

This phase 2 trial is testing a new formulation of the chemotherapy drug carmustine that doesn't contain ethanol, compared to the standard version that does. Both are used as part of the BEAM conditioning regimen before an autologous stem cell transplant in adults with Hodgkin or…

This phase 4 study is testing the safety and effectiveness of brentuximab vedotin (Adcetris) combined with standard chemotherapy (doxorubicin, vinblastine, and dacarbazine) in 124 Indian adults with untreated stage 3 or 4 classical Hodgkin lymphoma. Participants will receive the …

This phase 2 trial tests whether combining two drugs, pembrolizumab and brentuximab vedotin, can better shrink or eliminate Hodgkin lymphoma compared to standard chemotherapy (GDP) before a stem cell transplant. About 84 adults with relapsed or refractory classical Hodgkin lympho…

This study is testing an anti-PD-1 antibody (a type of immunotherapy) alone or combined with low-dose decitabine and/or standard chemotherapy in people whose cancers have come back or not responded to treatment. The trial includes patients with several cancer types, such as lymph…

This study tests a drug called tislelizumab in people with newly diagnosed Hodgkin lymphoma who are not able to receive standard chemotherapy. The goal is to see if the drug can shrink or control the cancer. About 28 participants will take part in this phase 2 trial.

This study tests a new approach to collect stem cells for transplant in people with multiple myeloma, Hodgkin lymphoma, or non-Hodgkin lymphoma. Instead of giving everyone the drug plerixafor, doctors will start with G-CSF alone and only add plerixafor if needed. The goal is to s…

This phase 2 trial is testing a shortened course of a drug combination called BrECADD for people with advanced Hodgkin lymphoma. The goal is to see if a shorter treatment can still control the cancer while reducing side effects. About 48 adults aged 18 to 60 will receive up to fo…

This phase 2 study tests a stem cell transplant procedure for people with Hodgkin or non-Hodgkin lymphoma, including those with HIV. Participants receive high-dose chemotherapy followed by an infusion of their own stem cells. The goal is to see if this radiation-free approach can…

This phase 2 trial tests a two-step, lower-intensity transplant method for people with various blood cancers. The goal is to see if this gentler approach reduces the chance of dying from the transplant itself. About 63 participants will receive a combination of radiation, chemoth…

This study tests a new type of immunotherapy called CAR-T cells, which are specially engineered to recognize and attack CD30, a protein found on Hodgkin lymphoma cells. The trial enrolls up to 31 adults whose cancer has returned or not responded to standard treatments. Participan…

This early-phase trial tests a new type of stem cell transplant for children with blood cancers or solid tumors that have relapsed or not responded to standard treatment. Doctors use a half-matched donor's stem cells, specially filtered to remove certain immune cells, and give th…

This study tests a new way to treat advanced Hodgkin lymphoma by combining the immunotherapy drug nivolumab with chemotherapy. Doctors use PET scans early in treatment to see how well it's working and adjust therapy accordingly. The goal is to improve outcomes while reducing side…

This program provides early access to an experimental drug called AVM0703 for people with various solid tumors and blood cancers, including hard-to-treat types like glioblastoma and metastatic breast cancer. It is available to patients in the US whose doctor requests it. So far, …

This early-phase study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in 8 adults with blood cancers or bone marrow failure who are at high risk of rejecting a stem cell transplant. The goal is to reduce DSA levels enough to allow the transplant t…

This study looks at whether a wearable heart monitor and a symptom questionnaire can accurately detect autonomic dysfunction—a condition affecting heart rate and blood pressure control—in survivors of childhood leukemia and lymphoma. Researchers will compare these remote methods …

This early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after a half-matched stem cell transplant. About 46 people with various blood cancers will take part…

This study tests whether a fecal microbiota transplant (FMT) can prevent graft-versus-host disease (GvHD) in 150 adults with blood cancers who receive a stem cell transplant. Patients get a single FMT enema within four weeks of transplant. The main goal is to see if FMT improves …

This phase 2 trial tests a vaccine called CMV-MVA Triplex, given to stem cell donors before they donate. The goal is to boost the donor's immunity against cytomegalovirus (CMV), which can then be passed to the transplant patient. Researchers hope this will prevent CMV infection i…

This study tests whether a 12-week high-intensity interval training (HIIT) program is practical for young people who have finished treatment for Hodgkin lymphoma. Twenty survivors aged 10 to 25 will do three 25-minute HIIT sessions per week. Researchers will track how many sign u…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

This study tests whether a tailored physical activity program can help lymphoma and breast cancer patients preserve their exercise ability, heart function, memory, and quality of life while undergoing cancer treatment. About 110 adults aged 18-85 with Hodgkin or non-Hodgkin lymph…

This study tests whether a Mediterranean diet and home-based exercise program can help lymphoma patients complete chemotherapy and reduce treatment-related side effects. Researchers will enroll 140 adults with untreated Hodgkin or non-Hodgkin lymphoma who need at least 6 cycles o…

This study tests a digital health program called AYA STEPS for adolescent and young adult cancer survivors. The program uses video sessions and online materials to teach skills for managing symptoms like pain, fatigue, and emotional distress, and to encourage follow-up care. Rese…

This study looks at whether a tailored exercise program can help older blood cancer survivors slow down the aging process. Researchers will enroll 180 people aged 50 and older who have had blood cancer. The goal is to see if participants can stick with the exercise plan and if it…

This study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a regist…

This study examines how social and genetic factors influence long-term health in 2000 adolescent and young adult survivors of Hodgkin or non-Hodgkin lymphoma. Researchers will collect blood samples and health information to identify risks for disease recurrence, other illnesses, …

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid. It includes 30 children and young adults with blood cancers who already take venetoclax this way. The goal is to measure drug levels in the blood and spinal fluid to ensure t…

This study collects blood and tissue samples from 200 adults with HIV and certain cancers (like Kaposi sarcoma, lymphoma, or anal cancer) to help researchers understand how HIV and cancer are connected. Participants donate samples, which are stored for future research. There is n…

This study follows 250 young adult cancer survivors to see how their social relationships and physical activity change over time and how these factors affect their quality of life. Participants wear an activity tracker and complete surveys. The goal is to learn how to better supp…

This study is a worldwide registry that follows 5,000 adults with breast cancer, blood cancers, or those on immune checkpoint inhibitors. Researchers collect medical records, lab results, and imaging to identify who is at risk for heart problems during or after cancer treatment. …

This study looks at how certain blood cell changes (called clonal hematopoiesis) after Hodgkin lymphoma treatment might be linked to later heart problems. Researchers will test blood samples from 190 survivors who received chemotherapy as children or young adults. The goal is to …

This study follows 250 children under 18 with Hodgkin lymphoma in Africa. Researchers want to see if simple, standardized treatment plans can work even when radiation therapy is not available. The goal is to improve access to effective care by adapting guidelines to local resourc…

This study creates a registry of 5,000 adults aged 50 and older with blood cancers like multiple myeloma and lymphoma. Researchers will track frailty, muscle loss, and other age-related health issues to better understand this group's needs. The goal is to gather information that …

This study looks at whether certain genetic markers can predict which young women (ages 18-38) with breast cancer or Hodgkin lymphoma are more likely to experience early menopause and infertility after chemotherapy. Researchers will analyze stored ovarian tissue from 50 patients …

This study looks at how young people (ages 6-25) with Hodgkin or non-Hodgkin lymphoma process certain medications. Researchers will give tiny, non-therapeutic doses of two common drugs (omeprazole and dextromethorphan) and measure how they are broken down in the body. The goal is…